Following a full submission
AWMSG advice |
|||
| Status: Not recommended | |||
Bromfenac (Yellox®) is not recommended for use within NHS Wales for the treatment of postoperative ocular inflammation following cataract extraction in adults. The applicant company did not present a sufficiently robust comparative clinical analysis or economic analysis to gain approval by AWMSG. No economic analysis was submitted. |
|||
|
|||
Medicine details |
|||
| Medicine name | bromfenac (Yellox®) | ||
| Formulation | 0.9 mg/ml eye drops | ||
| Reference number | 1025 | ||
| Indication | Treatment of postoperative ocular inflammation following cataract extraction in adults |
||
| Company | Bausch & Lomb UK Ltd | ||
| BNF chapter | Eye | ||
| Submission type | Full | ||
| Status | Not recommended | ||
| Advice number | 0614 | ||
| NMG meeting date | 22/01/2014 | ||
| AWMSG meeting date | 19/02/2014 | ||
| Ratification by Welsh Government | 07/05/2014 | ||
| Date of issue | 08/05/2014 | ||
| Date of last review | 08/05/2017 | ||